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Muscle Strengthening Activity 
A B S T R A C T   
Introduction: The objective of this randomized controlled trial (RCT) was to quantify the effects of eight weeks of 
World Health Organization and American College of Sports Medicine guidelines-based resistance exercise 
training (RET) among participants meeting criteria for subclinical, or analogue-GAD (AGAD) 
Methods: Forty-four participants (mean age (y): 25.4.6±4.9.2) were randomized to either an eight-week, fully- 
supervised, one-on-one RET intervention or wait-list control. AGAD status was determined using validated cut- 
scores for both the Psychiatric Diagnostic Screening Questionnaire-GAD subscale (≥6) and Penn State Worry 
Questionnaire (≥45). Remission, based on change in AGAD status, was assessed post-intervention, and quantified 
with number needed to treat (NNT). Primary analyses focused on participants missing outcome data at ≤1 time 
point (RET: n=12, Wait-list: n=15). RM-ANCOVA examined differences between RET and wait-list across time. 
Simple effects analysis decomposed significant interactions. Hedges’ d quantified magnitude of differences in 
change between conditions over time. 
Results: Attendance was 81% and compliance to the RET was 77%. Participants significantly increased strength 
(all d≥1.24, p≤0.006) with no adverse events. RET improved AGAD status (NNT=3, 95%CI: 2 to 7). Significant 
group X time interactions were found for worry (F(3,66) = 3.12, p≤0.043; d=0.93, 95%CI: 0.13 to 1.73) and 
anxiety symptoms (F(3,57.84)=2.91, ε=0.88, p≤0.045; d=0.71, 95%CI: -0.08 to 1.49). RET significantly reduced 
worry (mean difference=-6.49, p≤0.045) and anxiety symptoms (mean difference=-10.50, p≤0.001). 
Limitations: Limitations include a small sample size, and lack of attention-matched control condition. 
Conclusion: RET significantly improved AGAD severity, and elicited large, clinically meaningful improvements in 
worry and anxiety symptoms among young adults with AGAD.   
Introduction 
Anxiety disorders are prevalent (Bandelow & Michaelis, 2015), the 
sixth leading cause of disability in terms of years of life lived with 
disability (Baxter et al., 2014), and associated with poor health (Kessler 
et al., 2009). Anxiety disorders are economically burdensome (And-
lin-Sobocki & Wittchen, 2005) and poorly treated; 60% of patients with 
anxiety disorders do not positively respond to front-line interventions (i. 
e., cognitive behavioural therapy or pharmacotherapy) and many 
maintain residual symptoms following treatment (Bystritsky, 2006). 
Alternative or augmented treatments, such as physical activity and ex-
ercise, protect against anxiety symptoms and disorders (McDowell et al., 
2019). 
Physical activity is any bodily movement produced by skeletal 
muscles that results in energy expenditure; exercise is a subset of 
physical activity that is planned, structured, and repetitive, for the 
purpose of enhancing or maintaining one or more components of fitness 
(Caspersen et al., 1985). Exercise has well established effects on anxiety 
among otherwise healthy adults (Conn, 2010), chronically-ill adults 
(Herring et al., 2010), and anxiety disorder patients (Herring et al., 
2012). However, people with Generalized Anxiety Disorder (GAD) are 
less likely to meet the minimum recommended levels of physical activity 
than those without GAD (McDowell et al., 2018). Understudied 
compared to aerobic exercise, recent meta-analytic evidence showed 
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that resistance exercise training (RET) significantly reduces anxiety 
symptoms among both healthy adults (∆=0.50) and those with a phys-
ical/mental illness (∆=0.19) (Gordon et al., 2017). However, only two 
included RET trials randomized participants with any mental illness 
(Vlachopoulo et al., 2005; Herring et al., 2011), and only one random-
ized participants with clinically relevant anxiety pathology (Herring 
et al., 2011). These trials were neither designed in accordance with 
World Health Organization (WHO) (WHO, 2011) and American College 
of Sports Medicine (ACSM) (ACSM, 2009) guidelines for muscle 
strengthening exercise, nor designed to be ecologically-valid. The WHO 
recommends partaking in muscle-strengthening activities involving 
major muscle groups on two or more days a week (WHO, 2011); ACSM 
recommends progressive strength training a minimum of two 
non-consecutive days each week, with 1-3 sets of 8 to 12 repetitions for 
muscular strength benefits in novices (ACSM, 2009). 
The only randomized controlled trial (RCT) of RET among people 
with an anxiety disorder to date reported improved clinical severity 
(Herring et al., 2012) and associated symptoms (Herring et al., 2011) 
among young adult women with GAD. However, this trial featured only 
three lower-body, machine-based exercises, and was not designed in 
accordance with ACSM guidelines. The extent to which 
ecologically-valid RET (i.e., RET following currently recommended 
guidelines, and using standard movements that can be done at home or 
at a gym, including the RET frequency, composition, intensity, and 
progression) designed in accordance with WHO and ACSM guidelines 
improves these signs and symptoms of GAD, particularly among adults 
with prodromal, or analogue GAD (AGAD), is unknown (Gordon et al., 
2017). The median age of first onset of GAD is 30 (Kessler et al., 2012), 
and individuals who display elevated subclinical symptoms are more 
likely to develop clinically significant psychopathology (Ruscio et al., 
2007; Wolitzky-Taylor et al., 2014). 
Thus, the aim of this RCT was to quantify the effects of ecologically- 
valid RET on AGAD status and worry and anxiety symptoms among 
young adults with AGAD. Based on previous evidence (Herring et al., 
2012; Gordon et al., 2017), the authors hypothesized that RET would 
improve AGAD status, and elicit moderate magnitude reductions in 
worry and anxiety symptoms. 
Methods 
This pilot efficacy trial has adhered to the Consolidated Standards of 
Reporting Trials (CONSORT) Checklist (Schulz et al., 2010). 
Trial Design 
This manuscript presents findings from one of two parallel eight- 
week RCTs (ClinicalTrials.gov Identifier: NCT04116944). The full 
methods of these RCTs were reported previously (Gordon et al., 2020). 
The research protocol was approved by the University’s Research Ethics 
Committee (EHSREC No: 2017_03_18_EHS); all participants provided 
written informed consent prior to participation. This trial had rolling 
recruitment; data collection began January 18th, 2018 and concluded 
June 26th, 2019. 
Fig. 1. Flow chart of included participants.  
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Participants 
Participants were recruited from the surrounding area via posters, 
emails, and word of mouth. This trial had rolling recruitment; data 
collection for this trial began January 18th, 2018, and concluded June 
26th, 2019. Potential participants initially completed an electronic bat-
tery of questionnaires to establish eligibility; Fig. 1 presents a flowchart 
of participant recruitment. 
At baseline, participants completed a battery of online question-
naires, including the 10-item GAD subscale of the Psychiatric Diagnostic 
Screening Questionnaire (PDSQ-GAD) (Zimmerman & Mattia, 2001a), 
16-item Penn State Worry Questionnaire (PSWQ) (Meyer et al., 1990) 
and several other measures of signs and symptoms of GAD (i.e., 
depressive symptoms, irritability) (Rush et al., 2003; Craig et al., 2008). 
Participants were classified as either AGAD (PDSQ-GAD ≥6 and PSWQ 
≥45) or non-AGAD. Participants who did not meet or exceed both cut-off 
scores were considered non-AGAD, and diverted to a parallel RCT. 
Following AGAD categorization, participants were randomized, strati-
fied by sex, to RET or a wait-list control. 
Inclusion criteria were: i) age 18-40y; ii) scores that met criteria for 
AGAD (PDSQ-GAD ≥6 and PSWQ ≥45); iii) no medical contraindication 
to safe participation in RET; and, iv) no current pregnancy or lactation. 
Current RET involvement at baseline was not an exclusion criterion. 
Participants currently engaging in any form of resistance exercise 
training or physical activity were eligible for this study. To account for 
RET-specific familiarity/baseline physical activity levels, participants 
were asked, in reference to the time of the baseline assessment, how long 
they had currently been involved in a formalized resistance exercise 
training program. Participants’ previous self-reported RET involvement 
was measured in weeks to quantify participant training age. Although 
not an exclusion criterion, all participants had a training age of zero, 
meaning they were not currently involved in RET. 
Participants were not excluded if they were in treatment for anxiety, 
depression, or other mental health disorders (Rebar et al., 2017). Four 
participants currently receiving treatment for depression completed the 
trial (RET n=2, wait-list n=2). Treatment included pharmacotherapy 
(RET n=1, wait-list n=1), psychotherapy (wait-list n=1), or both (RET 
n=1). Six participants receiving treatment for depression withdrew 
(RET n=2, wait-list n=4). No participants reported receiving treatment 
for GAD. 
Participants randomized to both groups were advised to maintain 
their current levels of physical activity throughout the trial. Based on 
previous meta-analytic evidence of the small-to-moderate effect of RET 
on anxiety (Δ=0.31) (Gordon et al., 2017), a priori power analysis with 
G*Power 3.1 indicated a sample size of 24 (12 in each group) would 
provide >80% statistical power (two-tailed α=0.05, four repeated 
measures) to detect a small-to-moderate effect of exercise on worry 
symptoms (the hallmark symptom of GAD). As this study was considered 
a pilot efficacy trial for a larger more expansive trial, and attrition is 
common among physical activity interventions, recruitment continued 
until at least 10 participants were allocated to each group. At this point, 
12 participants were included in the RET condition, and 15 participants 
were included in the wait-list condition. 
RET Intervention 
RET was designed in accordance with WHO and ACSM guidelines 
(WHO, 2011; ACSM, 2009). The eight-week, twice-weekly intervention 
increased resistance progressively, such that the participant could 
complete between 8-12 repetitions before experiencing either fatigue, a 
deterioration in lifting form, or failure to complete a repetition. The 
eight exercises were barbell squat, barbell bench press, hexagon bar 
deadlift, seated dumbbell shoulder lateral raise, barbell bent over rows, 
dumbbell lunges, seated dumbbell curls, and abdominal crunches. Par-
ticipants randomized to RET completed a three-week, twice-weekly, 
familiarization process to ensure safety, correct lifting technique, and 
that the entirety of the eight-week intervention was delivered at the 
correct resistance starting at week one. Fully supervised exercise ses-
sions were approximately 25 minutes, on a one-to-one basis in a RET 
facility. All investigators were fully trained in delivering the exercise 
protocol consistently, as well as identifying proper and improper lifting 
mechanics. Participants completed primary and secondary outcome 
questionnaires supervised in the RET facility prior to RET bouts. Further 
specifics of the RET intervention have been previously published (Gor-
don et al., 2020). 
Control Condition 
Participants randomized to the wait-list completed primary and 
secondary outcome questionnaires supervised in the RET facility at 
baseline, week one, and week eight. Week four questionnaires were e- 
mailed to participants. Participants that completed the eight-week wait- 
list condition were subsequently offered the RET intervention, but no 
data were collected. 
Primary Outcome 
The primary outcome dependent variable of the trial was AGAD 
status, determined by scoring above or below validated cut-scores for 
both the PDSQ-GAD (≥6) and PSWQ (≥45). The PDSQ-GAD subscale 
has a sensitivity/specificity of 94/41%, strong internal consistency 
(α=0.89), positive and negative predictive value (25/98%), and test- 
retest reliability (α=0.58) (Zimmerman & Mattia, 2001a; 2001b). The 
PSWQ has a strong test-retest reliability (α=0.92) and internal consis-
tency (α=0.95). A cut score of 45 has shown sensitivity/specificity for 
GAD of 99/98% (Meyer et al., 1990). As RET can elicit rapid reductions 
in worry and anxiety symptoms (Herring et al., 2012), The PDSQ-GAD 
and PSWQ were assessed at baseline, week one, week four, and week 
eight. 
Secondary Outcome 
Secondary outcome dependent variables included worry, worry- 
engagement, and absence of worry assessed with the 16-item PSWQ. 
Total worry, worry-engagement, and absence of worry scores were 
calculated according to recommendations (Fresco et al., 2002). Worry 
symptoms were measured at baseline, week one, week four, and 
post-intervention. The PSWQ demonstrated good internal consistency 
α=0.84 (ICC=0.82, 95%CI: 0.70 to 0.90). Correlations between 
repeated measures at baseline and week one were 0.70 (p≤0.01) and 
0.78 (p≤0.001) for the RET and wait-list groups, respectively. 
Worry-engagement demonstrated good internal consistency α=0.81 
(ICC=0.78, 95%CI: 0.64 to 0.89). Correlations between repeated mea-
sures were 0.60 (p≤0.04) and 0.76 (p≤0.001) for RET and wait-list 
groups, respectively. Absence of worry demonstrated acceptable inter-
nal consistency α=0.65 (ICC=0.59, 95%CI: 0.30 to 0.79). Correlations 
between repeated measures were 0.33 (p≥0.29) and 0.72 (p≤0.002) for 
RET and wait-list groups, respectively. 
Anxiety symptoms were measured with the trait subscale of the 
State-Trait anxiety inventory (STAI-Y2) (Spielberger & Gorsuch, 1983). 
The 20-item STAI-Y2 is the most widely-used anxiety measure in the 
literature (Gordon et al., 2017), and has shown sensitivity to change in 
response to even short-term RET (Herring et al., 2011). Anxiety symp-
toms were measured in the same battery as the PDSQ-GAD and PSWQ at 
baseline, week one, week four, and week eight. The STAI-Y2 demon-
strated good internal consistency α=0.81 (ICC=0.89, 95%CI: 0.81 to 
0.94). Correlations between repeated measures were 0.64 (p≤0.02) and 
0.87 (p≤0.001) for RET and wait-list groups, respectively. 
Covariates 
Baseline physical activity was assessed using an online, self-report 
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version of the seven-day Physical Activity Recall (Blair et al., 1985). 
Participants reported time engaged in sleep, moderate, hard, and very 
hard activities during the prior week. Estimated energy expenditure was 
calculated as kilocalories per week. According to thresholds validated by 
Dishman and Steinhardt (1988), participants can be considered inactive 
(<245 kcals/week) to highly active (≥280 kcals/week). 
Intervention Fidelity and Manipulation Check 
Attendance was calculated by dividing the number of RET bouts 
attended by 16 (two sessions per week x eight weeks). Compliance to the 
RET protocol was calculated by dividing the number of sets in which at 
least eight repetitions were completed by 256 (two sets x eight exercises 
x two sessions per week x eight weeks), which represents the minimum 
prescribed number of repetitions. 
To quantify anticipated changes in strength as a manipulation check, 
and to facilitate setting of load, participants completed a five-repetition 
max (5RM) assessment for the barbell squat, barbell bench press, and 
hexagon bar deadlift at baseline and post-intervention. During the six 
familiarization sessions, participants completed two familiarizations 
with the 5RM process, and one maximal 5RM assessment. 
Statistical analyses 
Data analyses were performed using SPSS 25.0. Missing data for both 
the STAI-Y2 and PSWQ were 3.7%. Missing data for STAI-Y2 (n=5) and 
PSWQ (n=5) were imputed: sex and time-variant responses for each 
variable were entered as predictors into separate multiple linear 
regression models for condition, and predicted values were retained. 
Participants (n=16) were excluded if they were missing primary 
outcome data at >1 time point. Intention-to-treat analyses, and analyses 
of complete cases only are reported as sensitivity analyses. Changes in 
AGAD status, considered remission herein, were analysed using the 
number needed to treat (NNT) (Cook & Sackett, 1995). The NNT and 
associated 95%CIs were calculated as the inverse of the absolute risk 
reduction for RET compared with the wait-list condition. NNT was 
rounded up to the nearest whole number, and 95%CIs were converted 
from Hedges’ d effect size for worry symptoms (Cook & Sackett, 1995). 
Independent samples t-tests examined baseline differences between 
groups and sexes. The magnitude of baseline differences were quantified 
using Cohen’s d effect sizes (Rosenthal, 1994). Two group (RET/wait--
list) x four time (baseline/week one/week four/post-intervention) 
repeated measures ANCOVA examined differences between RET and 
wait-list; age, sex, and baseline physical activity were covariates. The 
Huynh-Feldt adjustment was applied when sphericity was violated. 
Significant interactions were decomposed using simple effects analysis. 
Standardized mean difference (SMD) quantified the magnitude of 
within-condition change. The magnitude of difference in outcome 
change between groups was quantified by Hedges’ d effect sizes and 
associated 95%CIs (Hedges & Olkin, 1985). Hedges’ d effect sizes were 
calculated by subtracting the mean change in the wait-list from the 
mean change in the RET condition, and dividing this difference by the 
pooled standard deviation of baseline scores; effect sizes were adjusted 
for small sample size bias and calculated such that improved outcomes 
in each condition and larger improvements among RET compared to 
wait-list resulted in positive effect sizes. Changes in strength were 
examined with paired-samples t-tests. Associations between changes in 
strength and changes in worry and anxiety symptoms were quantified 
using Pearson correlation coefficients of associations between change 
scores 
Results 
Table 1 presents baseline participant characteristics and differences 
between groups among included participants. There were no baseline 
differences between groups among included participants on any 
outcomes, supporting successful randomization. There were no baseline 
differences between sexes among included participants on any 
outcomes. 
Intervention Fidelity and Manipulation Check 
The average attendance to the RET intervention was 81% (13 out of 
16 sessions). The average compliance with RET was 77% (197 out of 256 
repetitions). These attendance and compliance rates indicate that par-
ticipants missed approximately three sessions over the intervention, but 
were compliant when they attended. No adverse events arose from trial 
participation. However, one participant randomized to RET reported a 
headache during an exercise bout. The investigator supervising the bout 
immediately stopped the session, and the participant subsequently 
withdrew from the trial after consulting with a physician. The average 
rating of perceived exertion was 14±2 (between somewhat hard and 
hard, range 6 to 20) (Heath, 1998); average muscle soreness was 4±2 
out of 10 (between mild soreness and some soreness present). As 
anticipated, participants in the RET intervention significantly increased 
their total strength (t(8)=-6.86, p≤0.001, Cohen’s d=2.29, mean in-
crease: 23.4%±11.8). 
Number Needed to Treat 
Based on AGAD remission, there was a NNT of 3 (95%CI: 2 to 17). 
For transparency, Table 2 indicates NNT values through alternative 
operational definitions of AGAD status. 
Worry Severity and Anxiety Symptoms 
Table 3 presents descriptives, standardized mean differences, and 
Hedges’ d (95%CI) for outcomes. Significant group X time interactions 
were found for worry symptoms (F(3,66)=3.60, p≤0.04; d=0.93, 95%CI: 
0.13 to 1.73), worry-engagement (F(3,66)=3.31, p≤0.03; d=0.98, 95%CI: 
0.18 to 1.79), and anxiety symptoms (F(3,57.84)=2.91, ε=0.88, p≤0.045; 
d=0.71, 95%CI: -0.08 to 1.49). RET significantly reduced worry symp-
toms (mean difference=-6.49, p≤0.04), non-significantly reduced worry 
engagement (mean difference=-5.49, p≥0.059), and significantly 
reduced anxiety symptoms (mean difference=-10.50, p≤0.001) from 
Table 1 









t p Cohen’s d 
% Female 66.67 66.67    
Age(y) 26.5(5.8) 26.7(4.9) -0.081 0.94 -0.03(-0.79 to 
0.73) 
Body Mass Index 24.4(4.1) 26.0(4.5) -0.97 0.34 -0.37(-1.14 to 
0.39) 
Symptoms of GAD 
(PDSQ-GAD) 








42.7(7.4) 40.7(5.9) 0.76 0.46 0.29(-0.47 to 
1.06) 
Absence of Worry 
(PSWQ-AW) 














-1.51 0.15 -0.58(-1.36 to 
0.19) 
SD=Standard Deviation; RET=Resistance Exercise Training; WL=Wait-list; 
PDSQ-GAD=Psychiatric Diagnostic Screening Questionnaire-Generalized Anxi-
ety Disorder subscale; PSWQ=Penn State Worry Questionnaire; PSWQ- 
WE=Penn State Worry Questionnaire-Worry Engagement; PSWQ-AW=Penn 
State Worry Questionnaire-Absence of Worry; STAI-Y2=Trait Anxiety 
Inventory. 
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baseline to post-intervention. There was no significant interaction for 
absence of worry (F(3,69)=1.16, p≥0.33; d=-0.58, 95%CI: -1.36 to 0.19). 
Changes in strength were not significantly associated with changes in 
worry symptoms (r(9)=0.20, p≤0.60), worry engagement (r(9)=0.29, 
p≤0.46), absence of worry (r(9)=-0.54, p≤0.13), or anxiety symptoms 
(r(9)=0.39, p≤0.30). Table 4 presents Hedges’ d (95%CI) for outcomes at 
each measurement time-point. 
The magnitude of reductions for worry symptoms (d=1.07, 95%CI: 
0.45 to 1.68), worry engagement (d=1.10, 95%CI: 0.48 to 1.72), 
absence of worry (d=-0.55, 95%CI: -1.15 to 0.04), and anxiety symp-
toms (d=0.87, 95%CI: 0.27 to 1.48) with intention-to-treat analysis did 
not differ from primary analyses. The magnitude of reductions also did 
not differ for worry symptoms (d=1.04, 95%CI: 0.19 to 1.89), worry 
engagement (d=1.13, 95%CI: 0.27 to 1.99), absence of worry (d=-0.32, 
95%CI:-1.23 to 0.49), and anxiety symptoms (d=0.64, 95%CI: -0.18 to 
1.46) using only complete cases. 
Discussion 
This RCT specifically addressed recent calls from the United States 
Physical Activity Guidelines Advisory Committee Scientific Report to 
conduct RCTs in individuals at different stages or severity of impairment 
(i.e., AGAD), to examine whether physical activity, in this case RET, 
delays or prevents disease onset and progression (United States Physical 
Activity Guidelines Advisory Committee, 2018). This is critically 
important, because intervention at early points on the severity spectrum 
may significantly reduce the probability of future clinical 
psychopathology (Wolitzky-Taylor et al., 2014). The cumulative evi-
dence supports the recommendations for prescription and end-user 
engagement in guidelines-based aerobic and RET as an efficacious 
alternative or augmented therapy for worry and anxiety symptoms. 
Ecologically-valid RET, designed according to WHO and ACSM 
guidelines, significantly improved AGAD status among young adults 
with AGAD. The NNT of three indicates that AGAD remission would be 
expected to occur for at least one of every three participants who would 
engage in this guidelines-based RET. This NNT of three is consistent with 
previous evidence among young women with GAD (Herring et al., 
2012). The NNT is smaller than previous meta-analytic evidence for 
antidepressant treatment in GAD (NNT=5.15) (Kapczinski et al., 2003), 
and consistent with the NNT for cognitive behavioural therapy in GAD 
(NNT=2.23) (Cuijpers et al., 2014). The consistency in NNT between 
RET and other frontline treatments for GAD directly supports RET as an 
alternative or augmentation therapy for AGAD and GAD. 
The large magnitude reductions in worry symptoms found here 
(d=0.93) are larger than previous evidence for RET for worry among 
young adult women with GAD (d=0.45) (Herring et al., 2012). The large 
magnitude reductions in anxiety symptoms (d=0.71) and worry symp-
toms are clinically meaningful, based on a frequently used response 
threshold of a 50% or greater reduction in baseline scores, or on a 
minimally important difference threshold of 0.5 standard deviation 
units (Rush et al., 2003). The magnitude of reductions in anxiety 
symptoms are larger than previous meta-analytic evidence for RET for 
anxiety among those with physical/mental illness (∆=0.19) (Gordon 
et al., 2017). The magnitude of reductions in anxiety symptoms are also 
larger than previous meta-analytic evidence for all/diverse types of 
exercise for otherwise healthy adults (∆=0.22) (Conn, 2010) and 
chronically-ill adults (∆=0.29) (Herring et al., 2012), and experimental 
Table 2 
Number needed to treat values of varying operational definitions of Analogue 
Generalized Anxiety Disorder status.  









PDSQ-GAD <6, OR PSWQ <45 6 2 3 
PDSQ-GAD <6, AND PSWQ 
<45 
2 1 10 
PDSQ-GAD <6 6 2 3 
PSWQ <45 2 1 10 
PSWQ Worry symptom 
reduction magnitude 
(Hedges’ d)   
3 
STAI-Y2 Anxiety symptom 
reduction magnitude 
(Hedges’ d)   
4 
PDSQ-GAD=Psychiatric Diagnostic Screening Questionnaire-Generalized Anxi-
ety Disorder subscale; PSWQ=Penn State Worry Questionnaire; STAI-Y2=Trait 
Anxiety Inventory. 
Table 3 
Changes in worry and anxiety symptoms from baseline.  
Outcome Group Baseline Week 1 SMD Hedges’ d 
from Baseline 
Week 4 SMD Hedges’ d 
from Baseline 
Week 8 SMD Hedges’ d 
from Baseline 
Worry Symptoms (PSWQ) RET 63.5(9.5) 59.3 
(13.1) 
0.45 0.69  
(-0.09 to 
1.47) 





0.78 0.93  
(0.13 to 1.73) 
WL 61.2(8.3) 63.2(7.4) -0.24 63.2 
(10.6) 
-0.24 62.3(8.9) -0.14 
Worry-Engagement (PSWQ- 
WE) 
RET 42.7(7.4) 39.5 
(11.1) 
0.43 0.73  
(-0.04 to 
1.52) 
38.3(8.4) 0.59 0.98  
(0.18 to 1.78) 
36.5(10.4) 0.83 0.98  
(0.18 to 1.79) 
WL 40.7(5.9) 42.6(5.3) -0.32 43.1(8.0) -0.39 41.3(6.9) -0.26 
Absence of Worry (PSWQ- 
AW) 
RET 20.8(2.7) 19.8(3.0) 0.40 0.15 
(-0.62 to 
0.91) 
20.3(2.3) 0.22 -0.07 
(-0.83 to 
0.68) 
22.8(8.9) -0.69 -0.58 
(-1.36 to 
0.19) 
WL 21.1(4.3) 20.6(2.9) 0.12 20.3(3.8) -0.2 20.9(3.2) -0.15 
















1.49) WL 55.1(9.1) 54.1(7.8) 0.12 53.8(9.6) 0.18 51.2(8.5) 0.43 
RM-ANCOVA controlling for sex, age, and non-intervention physical activity; *indicates a significant difference from the baseline score in simple effects analyse. 
SMD=Standardized Mean Difference; RET=Resistance Exercise Training; WL=Wait-list; STAI-Y2=Trait Anxiety Inventory; PSWQ=Penn State Worry Questionnaire; 
PSWQ-WE=Penn State Worry Questionnaire-Worry Engagement; PSWQ-AW= Penn State Worry Questionnaire-Absence of Worry. 
Table 4 
Changes in outcomes by time-points of intervention.  




Week 1 to Week 
4 
Hedges’ d 




0.69 (-0.09 to 
1.47) 
0.02 (-0.74 to 
0.78) 




0.73 (-0.04 to 
1.52) 
0.19 (-0.57 to 
0.95) 
0.004 (-0.76 to 
0.76) 
Absence of Worry 
(PSWQ-AW) 
0.15 (-0.62 to 
0.91) 
-0.28 (-1.04 to 
0.49) 






0.34 (-0.42 to 
1.11) 
0.21 (-0.55 to 
0.97) 
STAI-Y2=Trait Anxiety Inventory; PSWQ=Penn State Worry Questionnaire; 
PSWQ-WE=Penn State Worry Questionnaire-Worry Engagement; PSWQ-AW; 
Penn State Worry Questionnaire-Absence of Worry. 
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evidence for RET for anxiety among young adult women with diagnosed 
GAD (d=0.52) (Herring et al., 2011). This is the second RET trial to 
demonstrate large reductions in worry and anxiety symptoms among 
young adults with GAD or AGAD (Herring et al., 2012; Herring et al., 
2011), and the first ecologically-valid RET trial, designed in accordance 
with WHO and ACSM guidelines, to demonstrate such large reductions. 
The reductions in worry symptoms in the RET group were larger than 
predicted; specifically, the rapid, moderate-to-large magnitude 
improvement in worry symptoms across the familiarization sessions 
from baseline to week one of training were larger than predicted. 
Although the dose of RET during the three-week familiarization process 
was minimal, the reductions in worry symptoms that occurred in the 
three weeks following baseline to week one (d=0.69) are consistent with 
evidence that RET can elicit reductions in worry symptoms among 
young adult women with GAD in two weeks (d=0.33) (Herring et al., 
2012). The reductions in anxiety symptoms from baseline to week one 
(d=0.17) are consistent with the reductions in anxiety symptoms among 
young adult women with GAD in two weeks (d=0.14) (Herring et al., 
2011). 
Adherence of 81% and compliance to RET of 77% supports that the 
RET intervention was feasible and tolerable among young adults with 
AGAD. These attendance and compliance rates indicate that participants 
missed approximately three sessions over the intervention, but were 
compliant when they attended. The high attendance and compliance 
reported here, as well as exceedingly high attendance (100%) and 
compliance (99.1%) rates reported for the lone previous RCT of RET 
among young adult women with GAD (Herring et al., 2012), provides 
promising support for RET as an alternative/augmentation therapy. 
Changes in strength were not correlated with changes in worry or 
anxiety symptoms. Recent meta-analytic evidence supports significant 
improvements in strength are not required for mental health benefits 
(Gordon et al., 2017; 2018). However, as anticipated, participants 
showed large significant improvements in strength (all d≥1.24, 
p≤0.006). These associated strength changes may have important im-
plications specifically for young adults with AGAD. Given that GAD risk 
typically arises during the teen years and progresses relatively linearly 
into adulthood (Lieb, Becker, & Altamura, 2005), RET interventions 
targeting these adolescent and young adult populations, who may 
otherwise not be engaging in any muscle strengthening activity, are 
particularly important. Additionally, future trials including larger sam-
ples should investigate the relationship between changes in strength and 
changes in mental health outcomes in maximum tolerable doses and 
minimal effective doses of guidelines-based RET in healthy and clinical 
populations less willing to comply to progressive RET interventions. 
There are several potential mechanisms that may help to explain why 
large magnitude reductions in anxiety occurred in response to RET 
among young adults with AGAD. Although social interaction was 
rigorously controlled (Gordon et al., 2020), RET participants may have 
benefited from the increased amount of social interaction during the 
exercise bouts. Neurobiological theories involve systems that are 
involved in both how anxiety develops, and how exercise affects the 
brain (Dishman et al., 2006). Potential RET-specific mechanisms include 
increases in insulin-like growth factor 1 (IGF-1). Recent animal models 
showed that hippocampal IGF-1was increased in rats after RET, and not 
in wheel running (Cassilhas et al., 2012). Increase in serum IGF-1 is 
associated with neurogenesis, and reduced anxiety-like behaviours in 
mice. (Ding et al., 2006). More research is needed regarding the specific 
mechanisms underlying RET effects on anxiety and worry symptoms, 
particularly those that may be unique to RET, and unique to individuals 
with AGAD or anxiety disorders. 
Generalizability 
Although findings are based on a small sample of young adults, the 
anxiety and worry symptom reductions found here are generalizable 
other populations of young adults, and may have implications for 
middle-aged and older adults. Although the worldwide prevalence of 
GAD among those 15-45y ranges from 1.4-4.1% (Bandelow & Michaelis, 
2015), there is no information regarding the prevalence of AGAD in this 
population. However, of the 93 participants who completed the baseline 
screening, 51 (55%) met AGAD criteria, indicating high prevalence of 
elevated worry symptoms in the small population of potential partici-
pants. The population of young adults aged 18-40y in Ireland is ~1.5 
million (Central Statistics Office, 2016); based on the prevalence rate 
assessed here, 810,000 young adults in Ireland would be expected to 
meet criteria for AGAD. If the entirety of this population were compliant 
with guidelines-based RET, based on the AGAD remission demonstrated 
here (NNT=3), remission would be expected to occur in approximately 
270,000 young adults. Although it would be logistically impossible to 
provide one-on-one RET at such a large scale, there are several ways to 
engage in ACSM and WHO guidelines-based RET at minimal cost and 
equipment needs, or at home using only body-weight exercises. There-
fore, policy makers, universities, and organizations should devise ways 
to make RET accessible, and encourage all individuals not meeting 
guidelines to engage in aerobic activity and RET consistent with the 
guidelines of the WHO and ACSM for physical and mental health benefit. 
This RCT has clear implications for the efficacy of RET as an alter-
native or augmentation therapy for anxiety disorders among young 
adults, and the development of guidelines for treatment among those 
most at risk for developing anxiety disorders, particularly the prescrip-
tion of RET as an alternative or augmentation therapy among young 
adults with elevated worry. Clinicians should evaluate and monitor 
patients’ physical activity involvement, and encourage patients to 
engage in guidelines-based RET. Further, although the RET exercises are 
generalizable to the general population, there are myriad alternative 
RET options as well, including home-based RET, equipment free RET, or 
RET focused on muscular hypertrophy or power (ACSM, 2009). Clini-
cians should encourage patients to engage in guidelines-based RET as an 
alternative treatment for GAD, and augment other 
empirically-supported treatments for anxiety, such as cognitive behav-
ioural therapy and pharmacotherapy, with RET. 
Limitations 
Limitations include a lack of a time-matched, attention-control 
condition. Participants in the RET intervention may have benefited from 
the attention and social interaction provided to them not provided to the 
wait-list condition. Further, the lack of follow-up assessment limits the 
study’s ability to determine if reductions in symptoms are sustained. As 
this was a pilot efficacy trial, the sample size was small. Although this 
trial was sufficiently powered to detect small-to-moderate reductions in 
worry symptoms, future trials would benefit from larger sample sizes to 
explore potential sex-related response differences to RET and plausible 
mediators/moderators of response. Additionally, although participants 
met or exceeded established cut scores sensitive and specific to GAD, the 
use of blinded clinical interviews assessing the presence or absence of 
anxiety and related disorders would more rigorously assess baseline 
AGAD status. 
Conclusion 
Ecologically-valid, guidelines-based RET significantly improved 
AGAD status and resulted in moderate-to-large magnitude, clinically 
meaningful improvements in symptoms of worry and anxiety among 
young adults with elevated worry indicative of AGAD. Future trials 
should replicate and expand these findings to explore sex-related dif-
ferences, examine putative psychobiological mechanisms of the anxio-
lytic effects of RET, and augment other established treatments for 
anxiety, such as psychotherapy and pharmacotherapy, with RET. 
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